Gain Therapeutics (NASDAQ:GANX) Now Covered by Analysts at Scotiabank

Scotiabank assumed coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a sector outperform rating and a $12.00 target price on the stock.

Several other analysts also recently issued reports on the company. Roth Mkm restated a “buy” rating and set a $7.00 price objective on shares of Gain Therapeutics in a report on Tuesday, December 24th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, November 25th. Finally, Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Gain Therapeutics currently has a consensus rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Price Performance

NASDAQ GANX opened at $1.88 on Friday. The stock’s 50-day moving average price is $2.25 and its two-hundred day moving average price is $1.96. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The company has a market cap of $49.87 million, a PE ratio of -1.71 and a beta of 0.14. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $4.80.

Hedge Funds Weigh In On Gain Therapeutics

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares in the last quarter. Benedict Financial Advisors Inc. bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $35,000. Sprott Inc. bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $30,000. Northern Trust Corp grew its stake in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after buying an additional 39,642 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $65,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.